HENGRUI PHARMA (01276.HK): Makes A-Share Repurchase of 335,000 Shares for RMB 14,503,550
- The repurchase was executed at a highest price of RMB 43.58 per share and a lowest price of RMB 43.10 per share.
- The repurchase plan was approved at the tenth meeting of the Company's fourth board of directors on 19 August 2026, with a total repurchase amount of not less than RMB 1 billion and not more than RMB 2 billion.
- The repurchased shares will be used for the A-share employee share ownership plan, at a price of not more than RMB 81.78 per share, within a period ending 18 August 2027.
NewTimeSpace News: On 17 September 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) disclosed an overseas regulatory announcement that it repurchased 335,000 A shares through centralised bidding for the first time on 17 September 2026, representing 0.005% of the Company's total share capital, at a highest price of RMB 43.58 per share and a lowest price of RMB 43.10 per share, with a total payment of RMB 14,503,550 (excluding transaction costs).
The repurchase was made under a plan approved at the tenth meeting of the fourth board of directors on 19 August 2026, under which the Company uses its own funds to repurchase A shares through centralised bidding for the implementation of its A-share employee share ownership plan, at a price of not more than RMB 81.78 per share, for a total amount of not less than RMB 1 billion and not more than RMB 2 billion, within 12 months from the date of approval of the repurchase plan by the Board.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HENGRUI PHARMA (01276.HK): HRS-4139 Tablets Cleared for Clinical Trial in Moderate-to-Severe Plaque Psoriasis
- HENGRUI PHARMA (01276.HK): Recaticimab Cleared for Clinical Trials, Phase III Study Planned in Stroke Recurrence
- HENGRUI PHARMA (01276.HK): Marketing Application for Class 1 Innovative Drug SHR-2004 Injection Accepted by NMPA for VTE Prevention After Knee Replacement Surgery
- HENGRUI PHARMA (01276.HK): HER3 ADC Ruzaltatug Rezetecan granted breakthrough therapy designation
- HENGRUI PHARMA (01276.HK): Hetrombopag Olamine Tablets approved for two additional indications, becoming world's first TPO-RA approved for CTIT
